Your health and wellness goals are no different
Expert Testimony: We provide access to world-class gastroenterologists, neuro-ophthalmologists, and other medical professionals who can testify that the drugnot a pre-existing conditioncaused your injury
Mervyn Vergouwen: Bayer BV (investigator-initiated research, paid to instution) Poster Session II - INTRACRANIAL HEMORRHAGE 02.00 - INTRACRANIAL HEMORRHAGE - 02.01 - INTRACEREBRAL HAEMORRHAGE P770 - ESOC25-2045 TRACKING EARLY-DISEASE CHANGES IN DUTCH-TYPE HEREDITARY CAA: PRELIMINARY BASELINE RESULTS OF THE TRACK D-CAA STUDY Rosemarie van Dort 1 , Reinier van der Zwet 1 , Manon Schipper 1 , Neal Parikh 2 , Hamid Sohrabi 3 , Ralph Martins 4 , Steven Greenberg 5 , Marianne van Walderveen 1 , Matthias van Osch 1 , Marieke Wermer 6 1 Leiden University Medical Center, Leiden, Netherlands, 2 Alnylam Pharmaceuticals, Massachusetts, United States, 3 Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Perth, Australia, 4 Alzheimers Research Australia, & The Centre of Excellence for Alzheimers Disease Research and Care, Edith Cowan University, Perth, Australia, 5 Massachusetts General Hospital, Boston, United States, 6 University Medical Center Groningen, Groningen, Netherlands Background and Aims: This study aimed to investigate early disease biomarkers and natural history in D-CAA mutation-carriers and characterize disease progression over time
Notably, mechanistic insights into neuronal substrate metabolism provide a foundation for pathway-specific interventions
According to BCBS, consultation claims reported with CPT codes after Nov
